CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung “Unlikely Malignancy” result supported...
Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number...
Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program...
Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Research...
Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung
CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure ...
Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters ...
Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company’s noninvasive CyPath ® Lung diagnostic test
CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034 Precision Pathology Laboratory Services meets...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced...